Review Article | Published:

Cardiovascular effects of electronic cigarettes

Nature Reviews Cardiology volume 14, pages 447456 (2017) | Download Citation

Abstract

Cardiovascular safety is an important consideration in the debate on the benefits versus the risks of electronic cigarette (EC) use. EC emissions that might have adverse effects on cardiovascular health include nicotine, oxidants, aldehydes, particulates, and flavourants. To date, most of the cardiovascular effects of ECs demonstrated in humans are consistent with the known effects of nicotine. Pharmacological and toxicological studies support the biological plausibility that nicotine contributes to acute cardiovascular events and accelerated atherogenesis. However, epidemiological studies assessing Swedish smokeless tobacco, which exposes users to nicotine without combustion products, generally have not found an increased risk of myocardial infarction or stroke among users, but suggest that nicotine might contribute to acute cardiovascular events, especially in those with underlying coronary heart disease. The effects of aldehydes, particulates, and flavourants derived from ECs on cardiovascular health have not been determined. Although ECs might pose some cardiovascular risk to users, particularly those with existing cardiovascular disease, the risk is thought to be less than that of cigarette smoking based on qualitative and quantitative comparisons of EC aerosol versus cigarette smoke constituents. The adoption of ECs rather than cigarette smoking might, therefore, result in an overall benefit for public health.

Key points

  • The population risk versus benefit for use of electronic cigarettes (ECs) is strongly influenced by the relative safety of ECs compared with conventional cigarettes

  • The exposure of EC users to potentially toxic chemical emissions is difficult to quantify, given the numerous types of EC devices, different e-liquids, and disparities in individual use patterns

  • EC emissions of concern for cardiovascular health include nicotine, oxidizing chemicals, aldehydes (especially acrolein), and particulates

  • Nicotine might contribute to acute cardiovascular events, particularly in people with underlying cardiovascular disease, primarily by sympathetic neural stimulation and systemic release of catecholamines

  • The cardiovascular risk of EC use is likely to be much less than that of cigarette smoking

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Electronic cigarette use in the European Union: analysis of a representative sample of 27 460 Europeans from 28 countries. Addiction 111, 2032–2040 (2016).

  2. 2.

    , , & Electronic cigarette use among working adults — United States, 2014. MMWR Morb. Mortal. Wkly Rep. 65, 557–561 (2016).

  3. 3.

    , , & Nicotine without smoke-putting electronic cigarettes in context. BMJ 353, i1745 (2016).

  4. 4.

    & E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir. Med. 4, 116–128 (2016).

  5. 5.

    U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. NCBI (2010).

  6. 6.

    & The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob. Control 18, 324–332 (2009).

  7. 7.

    , , & Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst. Rev. 12, CD010216 (2014).

  8. 8.

    et al. Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: a longitudinal within-subjects observational study. Nicotine Tob Res. 19, 160–167 (2017).

  9. 9.

    & Modeling the health effects of expanding e-cigarette sales in the United States and United Kingdom: a Monte Carlo analysis. JAMA Intern. Med. 175, 1671–1680 (2015).

  10. 10.

    et al. Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. JAMA 314, 700–707 (2015).

  11. 11.

    et al. The application of a decision-theoretic model to estimate the public health impact of vaporized nicotine product initiation in the United States. Nicotine Tob. Res. 19, 149–159 (2016).

  12. 12.

    & Electronic cigarettes: product characterisation and design considerations. Tob. Control 23 (Suppl. 2), ii4–ii10 (2014).

  13. 13.

    , , , & Evaluation of electronic cigarette use (vaping) topography and estimation of liquid consumption: implications for research protocol standards definition and for public health authorities' regulation. Int. J. Environ. Res. Public Health 10, 2500–2514 (2013).

  14. 14.

    , , & Electronic cigarette topography in the natural environment. PLoS ONE 10, e0129296 (2015).

  15. 15.

    et al. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. Tob. Control (2016).

  16. 16.

    , , , & Chemical composition and evaluation of nicotine, tobacco alkaloids, pH, and selected flavors in E-cigarette cartridges and refill solutions. Nicotine Tob. Res. 17, 1270–1278 (2015).

  17. 17.

    et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob. Control 23, 133–139 (2014).

  18. 18.

    , , , & Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol. PLoS ONE 8, e57987 (2013).

  19. 19.

    et al. Emissions from electronic cigarettes: key parameters affecting the release of harmful chemicals. Environ. Sci. Technol. 50, 9644–9651 (2016).

  20. 20.

    , , , & Hidden formaldehyde in e-cigarette aerosols. N. Engl. J. Med. 372, 392–394 (2015).

  21. 21.

    , , & Determination of carbonyl compounds generated from the E-cigarette using coupled silica cartridges impregnated with hydroquinone and 2,4-dinitrophenylhydrazine, followed by high-performance liquid chromatography. Anal. Sci. 29, 1219–1222 (2013).

  22. 22.

    et al. Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. Nicotine Tob. Res. 16, 1319–1326 (2014).

  23. 23.

    , & E-cigarettes generate high levels of aldehydes only in 'dry puff' conditions. Addiction 110, 1352–1356 (2015).

  24. 24.

    et al. Effects of switching to electronic cigarettes with and without concurrent smoking on exposure to nicotine, carbon monoxide, and acrolein. Cancer Prev. Res. (Phila.) 8, 873–878 (2015).

  25. 25.

    et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob. Res. 17, 704–709 (2015).

  26. 26.

    et al. Nicotine, carcinogen, and toxin exposure in long-term E-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann. Intern. Med. (2017).

  27. 27.

    et al. Highly reactive free radicals in electronic cigarette aerosols. Chem. Res. Toxicol. 28, 1675–1677 (2015).

  28. 28.

    & New insights into pollution and the cardiovascular system: 2010 to 2012. Circulation 127, 1903–1913 (2013).

  29. 29.

    , , , & Real-time measurement of electronic cigarette aerosol size distribution and metals content analysis. Nicotine Tob. Res. 18, 1895–1902 (2016).

  30. 30.

    et al. Comparison of the aerosol produced by electronic cigarettes with conventional cigarettes and the shisha. Rev. Mal. Respir. 30, 752–757 (in French) (2013).

  31. 31.

    , & Flavorings in electronic cigarettes: an unrecognized respiratory health hazard? JAMA 312, 2493–2494 (2014).

  32. 32.

    et al. Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol. In Vitro 28, 198–208 (2014).

  33. 33.

    et al. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci. Rep. 4, 4133 (2014).

  34. 34.

    , , , & Nicotine delivery to users from cigarettes and from different types of e-cigarettes. Psychopharmacology (Berl.) 234, 773–779 (2017).

  35. 35.

    & Cardiovascular toxicity of nicotine: implications for electronic cigarette use. Trends Cardiovasc. Med. 26, 515–523 (2016).

  36. 36.

    Nicotine addiction. N. Engl. J. Med. 362, 2295–2303 (2010).

  37. 37.

    , , , & The Yin and Yang of non-neuronal alpha7-nicotinic receptors in inflammation and autoimmunity. Curr. Drug Targets 13, 644–655 (2012).

  38. 38.

    & Nicotine and pathological angiogenesis. Life Sci. 91, 1058–1064 (2012).

  39. 39.

    , & Chronic exposure to nicotine impairs cholinergic angiogenesis. Vasc. Med. 15, 47–54 (2010).

  40. 40.

    & Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J. Am. Coll. Cardiol. 29, 1422–1431 (1997).

  41. 41.

    et al. Smoking produces rapid rise of [11C]nicotine in human brain. Psychopharmacology (Berl.) 209, 383–394 (2010).

  42. 42.

    Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 83, 531–541 (2008).

  43. 43.

    , & Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57, 79–115 (2005).

  44. 44.

    , , & A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol. Biomarkers Prev. 19, 1945–1953 (2010).

  45. 45.

    et al. Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. Addiction 111, 535–544 (2016).

  46. 46.

    Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch. Intern. Med. 154, 989–995 (1994).

  47. 47.

    et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N. Engl. J. Med. 335, 1792–1798 (1996).

  48. 48.

    et al. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc. Drugs Ther. 12, 239–244 (1998).

  49. 49.

    , , , & Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am. J. Cardiol. 95, 976–978 (2005).

  50. 50.

    , , , & Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 129, 28–41 (2014).

  51. 51.

    et al. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation 83, 1698–1704 (1991).

  52. 52.

    et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation 122, 1520–1544 (2010).

  53. 53.

    et al. Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur. J. Epidemiol. 27, 771–779 (2012).

  54. 54.

    & Risk of incident cardiovascular disease among users of smokeless tobacco in the Atherosclerosis Risk in Communities (ARIC) study. Am. J. Epidemiol. 172, 600–605 (2010).

  55. 55.

    et al. Discontinuation of smokeless tobacco and mortality risk after myocardial infarction. Circulation 130, 325–332 (2014).

  56. 56.

    , , , & Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. J. Intern. Med. 250, 492–501 (2001).

  57. 57.

    et al. Smokeless tobacco (snus) and risk of heart failure: results from two Swedish cohorts. Eur. J. Prev. Cardiol. 19, 1120–1127 (2012).

  58. 58.

    et al. Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation. Epidemiology 25, 872–876 (2014).

  59. 59.

    , & Use of smokeless tobacco and risk of cardiovascular disease: a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 23, 1970–1981 (2016).

  60. 60.

    et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J. Am. Coll. Cardiol. 66, 1378–1391 (2015).

  61. 61.

    , & Smoking and mortality — beyond established causes. N. Engl. J. Med. 372, 631–640 (2015).

  62. 62.

    et al. Smoking and cardiac structure and function in the elderly: the ARIC study (Atherosclerosis Risk in Communities). Circ Cardiovasc. Imaging 9, e004950 (2016).

  63. 63.

    Epidemiology of smoking-induced cardiovascular disease. Prog. Cardiovasc. Dis. 46, 11–29 (2003).

  64. 64.

    , , , & Association of smoking with the risk of incident atrial fibrillation: a meta-analysis of prospective studies. Int. J. Cardiol. 218, 259–266 (2016).

  65. 65.

    et al. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure. Am. J. Cardiol. 105, 1336–1338 (2010).

  66. 66.

    et al. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J. Cardiovasc. Electrophysiol. 17, 931–936 (2006).

  67. 67.

    & Implications of cigarette smoking for the management of patients with acute coronary syndromes. Prog. Cardiovasc. Dis. 46, 1–9 (2003).

  68. 68.

    et al. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure-response relationship. Circulation 120, 941–948 (2009).

  69. 69.

    & Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 34, 509–515 (2014).

  70. 70.

    & The biology behind the atherothrombotic effects of cigarette smoke. Nat. Rev. Cardiol. 10, 219–230 (2013).

  71. 71.

    & Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler. Thromb. Vasc. Biol. 33, 1460–1467 (2013).

  72. 72.

    , & A new look at radicals in cigarette smoke. Anal. Chem. 79, 5103–5106 (2007).

  73. 73.

    Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog. Cardiovasc. Dis. 46, 91–111 (2003).

  74. 74.

    E-cigarettes and cardiovascular disease risk: evaluation of evidence, policy implications, and recommendations. Curr. Cardiovasc. Risk Rep. 10, 24 (2016).

  75. 75.

    Use of hazard indices for a theoretical evaluation of cigarette smoke composition. Chem. Res. Toxicol. 25, 794–810 (2012).

  76. 76.

    & Arteriosclerotic plaque development is 'promoted' by polynuclear aromatic hydrocarbons. Carcinogenesis 9, 2185–2189 (1988).

  77. 77.

    et al. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 121, 2331–2378 (2010).

  78. 78.

    et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 94, 2850–2855 (1996).

  79. 79.

    & A single 4 mg dose of nicotine decreases heart rate variability in healthy nonsmokers: implications for smoking cessation programs. Nicotine Tob. Res. 13, 369–372 (2011).

  80. 80.

    et al. Hormonal contraception among electronic cigarette users and cardiovascular risk: a systematic review. Contraception 93, 190–208 (2016).

  81. 81.

    , , , & Acute effects of using an electronic nicotine-delivery device (electronic cigarette) on myocardial function: comparison with the effects of regular cigarettes. BMC Cardiovasc. Disord. 14, 78 (2014).

  82. 82.

    & Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Regul. Toxicol. Pharmacol. 71, 24–34 (2015).

  83. 83.

    , , & Evaluation of changes in hemodynamic parameters after the use of electronic nicotine delivery systems among regular cigarette smokers. Prz. Lek. 69, 841–845 (in Polish) (2012).

  84. 84.

    et al. Efficiency and safety of an electronic cigareTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS ONE 8, e66317 (2013).

  85. 85.

    , , & Nicotine concentrations with electronic cigarette use: effects of sex and flavor. Nicotine Tob. Res. 17, 473–478 (2015).

  86. 86.

    et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Intern. Emerg. Med. 11, 85–94 (2016).

  87. 87.

    et al. Electronic cigarette smoking increases aortic stiffness and blood pressure in young smokers. J. Am. Coll. Cardiol. 67, 2802–2803 (2016).

  88. 88.

    et al. Influence of inhaled nicotine source on arterial stiffness. Prz. Lek. 71, 572–575 (2014).

  89. 89.

    , , , & Cigarette smoke but not electronic cigarette aerosol activates a stress response in human coronary artery endothelial cells in culture. Drug Alcohol Depend. 163, 256–260 (2016).

  90. 90.

    et al. Vapours of US and EU market leader electronic cigarette brands and liquids are cytotoxic for human vascular endothelial cells. PLoS ONE 11, e0157337 (2016).

  91. 91.

    et al. Acute impact of tobacco versus electronic cigarette smoking on oxidative stress and vascular function. Chest 150, 606–612 (2016).

  92. 92.

    et al. Electronic cigarettes increase endothelial progenitor cells in the blood of healthy volunteers. Atherosclerosis 255, 179–185 (2016).

  93. 93.

    , , & Endothelial progenitor cells participate in nicotine-mediated angiogenesis. J. Am. Coll. Cardiol. 48, 2553–2560 (2006).

  94. 94.

    Electronic cigarettes increase EPCs. Atherosclerosis 255, 119–121 (2016).

  95. 95.

    et al. Increased cardiac sympathetic activity and oxidative stress in habitual electronic cigarette users: implications for cardiovascular risk. JAMA Cardiol. (2017).

  96. 96.

    et al. Acute effects of electronic and tobacco cigarette smoking on complete blood count. Food Chem. Toxicol. 50, 3600–3603 (2012).

  97. 97.

    & Will chronic e-cigarette use cause lung disease? Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L1398–L1409 (2015).

  98. 98.

    et al. Vapors produced by electronic cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS ONE 10, e0116732 (2015).

  99. 99.

    et al. E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. Am. J. Physiol. Lung Cell. Mol. Physiol. 311, L135–L144 (2016).

  100. 100.

    et al. Cohort study of electronic cigarette use: effectiveness and safety at 24 months. Tob. Control (2016).

  101. 101.

    , , , & Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. Int. J. Environ. Res. Public Health 11, 4356–4373 (2014).

  102. 102.

    , , & Paroxysmal atrial fibrillation following electronic cigarette use in an elderly woman. Clinical Geriatrics 20, 28–32 (2012).

  103. 103.

    et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 382, 1629–1637 (2013).

  104. 104.

    , , , & Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction 109, 1531–1540 (2014).

  105. 105.

    et al. Electronic cigarettes: a policy statement from the American Heart Association. Circulation 130, 1418–1436 (2014).

  106. 106.

    & Cigarette smoking and coronary blood flow. Prog. Cardiovasc. Dis. 45, 395–404 (2003).

  107. 107.

    et al. Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin. Pharmacol. Ther. 67, 391–397 (2000).

  108. 108.

    et al. Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J. Am. Coll. Cardiol. 39, 251–256 (2002).

  109. 109.

    , , & Activation of platelets exposed to shear stress in the presence of smoke extracts of low-nicotine and zero-nicotine cigarettes: the protective effect of nicotine. Nicotine Tob. Res. 6, 835–841 (2004).

  110. 110.

    , , & Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J. Am. Coll. Cardiol. 22, 1159–1167 (1993).

  111. 111.

    , , & Reduced-nicotine cigarettes increase platelet activation in smokers in vivo: a dilemma in harm reduction. Nicotine Tob. Res. 10, 1737–1744 (2008).

  112. 112.

    et al. Myocardial infarction accelerates atherosclerosis. Nature 487, 325–329 (2012).

  113. 113.

    et al. Nicotine increases ventricular vulnerability to fibrillation in hearts with healed myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 278, H2124–H2133 (2000).

  114. 114.

    , , & Ventricular arrhythmias during 24-h ambulatory ECG recording: incidence, risk factors and prognosis in men with and without a history of cardiovascular disease. J. Intern. Med. 246, 363–372 (1999).

  115. 115.

    & Smoking and smoking cessation — the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 201, 225–235 (2008).

  116. 116.

    & Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors. Int. J. Obes. Relat. Metab. Disord. 25, 1225–1232 (2001).

  117. 117.

    et al. Effect of cigarette smoking on insulin resistance risk. Ann. Cardiol. Angeiol. (Paris) 65, 21–25 (2016).

  118. 118.

    et al. Activation of AMPKalpha2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. Nat. Med. 21, 373–382 (2015).

  119. 119.

    , , , & Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298, 2654–2664 (2007).

Download references

Acknowledgements

The authors thank Dr Gideon St. Helen (University of California San Francisco, USA), for critical review of the manuscript and Tyson Douglass (University of California San Francisco, USA) for editorial assistance. The preparation of this Review is supported by US Public Health Service grants P50 CA180890 from the National Cancer Institute and Food and Drug Administration Center for Tobacco Products.

Author information

Affiliations

  1. Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, Departments of Medicine and Biopharmaceutical Sciences, University of California, 1001 Potrero Avenue #3316, San Francisco, California 94110, USA.

    • Neal L. Benowitz
  2. Center for Tobacco Control Research and Education, University of California, 530 Parnassus Avenue, San Francisco, California 94117, USA.

    • Neal L. Benowitz
  3. Louisiana State University School of Medicine, Department of Emergency Medicine, Lallie Kemp Regional Medical Center, 52579 US-51, Independence, Louisiana 70443, USA.

    • Joseph B. Fraiman

Authors

  1. Search for Neal L. Benowitz in:

  2. Search for Joseph B. Fraiman in:

Contributions

Both authors researched data for the article, discussed the content, wrote the manuscript, and reviewed/edited it before submission.

Competing interests

N.L.B. has been a consultant to GlaxoSmithKline and Pfizer, pharmaceutical companies that market medications to aid smoking cessation, and has served as a paid expert witness in litigation against tobacco companies. J.B.F. declares no competing interests.

Corresponding author

Correspondence to Neal L. Benowitz.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrcardio.2017.36

Further reading